ArticleThe Lancet. Neurology2017
Large-scale identification of clinical and genetic predictors of motor progression in patients with newly diagnosed Parkinson's disease: a longitudinal cohort study and validation.
Article in The Lancet. Neurology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01141023 (The Parkinson's Progression Markers Initiative), which is not on this map. Cited by 96 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
The Parkinson's Progression Markers Initiative (PPMI)
Who cites it
96 citing papers in PubMed, 4 syntheses or guidelines pooled it, 158 citations in OpenAlex.
- Genome-Wide Association Studies of Cognitive and Motor Progression in Parkinson's Disease.Movement disorders : official journal of the Movement Disorder Society · 2021Pooled it
- Meta-analysis and field synopsis of genetic variants associated with the risk and severity of acute pancreatitis.BJS open · 2020Pooled it
- Pooled it
- No evidence for DNM3 as genetic modifier of age at onset in idiopathic Parkinson's disease.Neurobiology of aging · 2019Pooled it
- Measurement fidelity, not model complexity, governs individual cognitive trajectory prediction in Parkinson's disease.NPJ digital medicine · 2026Article
- Peripheral inflammation predicts motor, cognitive, and disease progression in Parkinson's disease: A 4-year longitudinal study from the PPMI cohorts.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2026Article
- PARQ: A Complexity-Consensus Aware Automatic Assessment of Motor Disease Severity in Parkinson's Disease.Research square · 2026Article
- D-mannose alleviates rotenone-induced PD mouse model through microbiota-gut-brain axis.Scientific reports · 2026Article
- Parkinson's research with inclusion, diversity and equity (PRIDE): examining Parkinson's disease symptoms among LGBTQ+ and non-LGBTQ+ adults.Frontiers in public health · 2026Article
- The patient-centric development of an inclusive multi-arm multi-stage trial for Parkinson's disease.Brain communications · 2026Article
- Parkinson's Disease: Bridging Gaps, Building Biomarkers, and Reimagining Clinical Translation.Cells · 2025Review
- Safety and tolerability of intravenous liposomal GM1 in patients with Parkinson disease: A single-center open-label clinical phase I trial (NEON trial).PLoS medicine · 2025Article
- Addressing the need for standardization of symptomatic medication documentation in Parkinson's disease clinical research: A call to action.Journal of Parkinson's disease · 2025Review
- Association between striatal amyloid deposition and motor prognosis in Parkinson's disease.European journal of neurology · 2024Article
- Risk for Mortality in High versus Low Antiparkinsonian Therapy Dose During the First Year of Parkinson's Disease: A Real-World Study.Advances in therapy · 2024Article
- Neuroimaging and fluid biomarkers in Parkinson's disease in an era of targeted interventions.Nature communications · 2024Review
- An Artificial Neural Network Predicts Gender Differences of Motor and Non-Motor Symptoms of Patients with Advanced Parkinson's Disease under Levodopa-Carbidopa Intestinal Gel.Medicina (Kaunas, Lithuania) · 2024Observational
- Association between sex and Huntington's disease: an updated review on symptomatology and prognosis of neurodegenerative disorders.Wiener medizinische Wochenschrift (1946) · 2024Review
- Cortical thickness and white matter microstructure predict freezing of gait development in Parkinson's disease.NPJ Parkinson's disease · 2024Article
- Investigating trial design variability in trials of disease-modifying therapies in Parkinson's disease: a scoping review protocol.BMJ open · 2023Article
36 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
11 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundBetter understanding and prediction of progression of Parkinson's disease could improve disease management and clinical trial design. We aimed to use longitudinal clinical, molecular, and genetic data to develop predictive models, compare potential biomarkers, and identify novel predictors for motor progression in Parkinson's disease. We also sought to assess the use of these models in the design of treatment trials in Parkinson's disease.
methodsA Bayesian multivariate predictive inference platform was applied to data from the Parkinson's Progression Markers Initiative (PPMI) study (NCT01141023). We used genetic data and baseline molecular and clinical variables from patients with Parkinson's disease and healthy controls to construct an ensemble of models to predict the annual rate of change in combined scores from the Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) parts II and III. We tested our overall explanatory power, as assessed by the coefficient of determination (R
findings117 healthy controls and 312 patients with Parkinson's disease from the PPMI study were available for analysis, and 317 patients with Parkinson's disease from LABS-PD were available for validation. Our model ensemble showed strong performance within the PPMI cohort (five-fold cross-validated R
interpretationOur model ensemble confirmed established and identified novel predictors of Parkinson's disease motor progression. Improvement of existing prognostic models through machine-learning approaches should benefit trial design and evaluation, as well as clinical disease monitoring and treatment.
fundingMichael J Fox Foundation for Parkinson's Research and National Institute of Neurological Disorders and Stroke.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.